Lytix Biopharma AS reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported revenue was NOK 1.62 million compared to NOK 0.719 million a year ago. Net loss was NOK 29.2 million compared to NOK 16.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.7 NOK | +4.69% | +11.67% | +37.86% |
05-30 | Transcript : Lytix Biopharma AS, Q1 2024 Earnings Call, May 30, 2024 | |
05-30 | Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+37.86% | 30.2M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- LYTIX Stock
- News Lytix Biopharma
- Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022